Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Pollard

Showing results (71-80 of 679) with videos related to

Pageof 68
Sort By:
BMJ (Clinical Research Ed.)|August 8, 2006
Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trialLinda Diggle, Jonathan J Deeks, Andrew J Pollard
Frontiers in Immunology|October 11, 2017
The Clinical Application of MicroRNAs in Infectious DiseaseRuth E Drury, Daniel O'Connor, Andrew J Pollard
Genome Medicine|November 12, 2015
The use of systems biology and immunological big data to guide vaccine developmentChristoph J Blohmke, Daniel O'Connor, Andrew J Pollard
Archives of Disease in Childhood|October 8, 2024
New programme to prevent bronchiolitis in infantsAndrew J Pollard, Mary Elizabeth Ramsay, Conall Watson
Frontiers in Microbiology|January 8, 2015
Why the development of effective typhoid control measures requires the use of human challenge studiesClaire Jones, Thomas C Darton, Andrew J Pollard
Lancet (London, England)|June 29, 2024
Towards paratyphoid control: the vital role of the challenge modelNaina McCann, Margarete Paganotti Vicentine, Andrew J Pollard
The Lancet. Infectious Diseases|February 27, 2021
Strategies for typhoid conjugate vaccines in endemic nations - Authors' replyVirginia E Pitzer, Andrew J Pollard, Joke Bilcke
Current Opinion in Infectious Diseases|August 24, 2018
Typhoid and paratyphoid fever: a call to actionMalick M Gibani, Carl Britto, Andrew J Pollard
Vaccine|May 30, 2009
Quadrivalent meningococcal conjugate vaccinesDavid Pace, Andrew J Pollard, Nancy E Messonier
The New England Journal of Medicine|July 21, 2021
ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. ReplyShabir A Madhi, Alane Izu, Andrew J Pollard
Pageof 68

Showing results (71-80 of 679) with videos related to

Sort By:
Pageof 68
BMJ (Clinical Research Ed.)|August 8, 2006
Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trialLinda Diggle, Jonathan J Deeks, Andrew J Pollard
Frontiers in Immunology|October 11, 2017
The Clinical Application of MicroRNAs in Infectious DiseaseRuth E Drury, Daniel O'Connor, Andrew J Pollard
Genome Medicine|November 12, 2015
The use of systems biology and immunological big data to guide vaccine developmentChristoph J Blohmke, Daniel O'Connor, Andrew J Pollard
Archives of Disease in Childhood|October 8, 2024
New programme to prevent bronchiolitis in infantsAndrew J Pollard, Mary Elizabeth Ramsay, Conall Watson
Frontiers in Microbiology|January 8, 2015
Why the development of effective typhoid control measures requires the use of human challenge studiesClaire Jones, Thomas C Darton, Andrew J Pollard
Lancet (London, England)|June 29, 2024
Towards paratyphoid control: the vital role of the challenge modelNaina McCann, Margarete Paganotti Vicentine, Andrew J Pollard
The Lancet. Infectious Diseases|February 27, 2021
Strategies for typhoid conjugate vaccines in endemic nations - Authors' replyVirginia E Pitzer, Andrew J Pollard, Joke Bilcke
Current Opinion in Infectious Diseases|August 24, 2018
Typhoid and paratyphoid fever: a call to actionMalick M Gibani, Carl Britto, Andrew J Pollard
Vaccine|May 30, 2009
Quadrivalent meningococcal conjugate vaccinesDavid Pace, Andrew J Pollard, Nancy E Messonier
The New England Journal of Medicine|July 21, 2021
ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. ReplyShabir A Madhi, Alane Izu, Andrew J Pollard
Pageof 68